No IND application has been filed to study Essiac

To conduct clinical drug research in the United States, researchers must file an Investigational New Drug (IND) application with the FDA. An IND application must also be made for clinical evaluation of dietary supplements as agents for the treatment or prevention of disease.

The FDA’s IND process is confidential, and the existence of an IND application can be disclosed only by the applicants. To date, no investigator has announced filing an IND application to study either Essiac or FlorEssence (substances that have been used in attempting to treat asbestos-related mesothelioma) in the treatment of patients with cancer.

The information we provide on weitzlux.com is for general educational purposes only. None of our website pages should be construed as an attempt to diagnose, prescribe, or recommend, in any manner, a treatment for any health ailment or condition. Please be sure to consult your own doctor regarding your medical treatment. This information is not a replacement for a thorough consultation and examination from a licensed health professional.

You may be visiting our website because you have been recently diagnosed with a health concern related to asbestos. Such conditions include mesothelioma, asbestosis and lung cancer.

Weitz & Luxenberg is a leading plaintiffs' law firm that has represented people affected by mesothelioma for over 20 years. Men and women diagnosed with mesothelioma or lung cancer caused by asbestos exposure may be entitled to compensation from the companies responsible for their disease.

If you would like a free consultation or more information about your legal options, please complete the form on this page, and a representative of our law firm will contact you as soon as possible.